Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elixinol WellnessASX:EXL EV-to-EBITDA is -1.00 as of Jul. 20, 2026. The stock has 7 warning signs investors should review. Among 741 Drug Manufacturers companies, Elixinol Wellness ranks worse than 134952.63% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Elixinol Wellness's enterprise value is A$4.73 Mil.
Elixinol Wellness's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-4.75 Mil. Therefore, Elixinol Wellness's EV-to-EBITDA for today is -1.00.
The historical rank and industry rank for Elixinol Wellness's EV-to-EBITDA or its related term are showing as below:
ASX:EXL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3727.46 Med: -0.53 Max: 0.53
Current: -1
During the past 8 years, the highest EV-to-EBITDA of Elixinol Wellness was 0.53. The lowest was -3727.46. And the median was -0.53.
ASX:EXL's EV-to-EBITDA is ranked worse than 100% of 741
companies
in the Drug Manufacturers industry
Industry Median: 13.1
vs ASX:EXL: -1.00
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Elixinol Wellness's PE Ratio (TTM) for today is calculated as:
Elixinol Wellness's share price for today is A$0.006.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Elixinol Wellness's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.022.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Elixinol Wellness's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:EXL vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Elixinol Wellness's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elixinol Wellness EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elixinol Wellness's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Elixinol Wellness's EV-to-EBITDA falls into.
Elixinol Wellness's current Enterprise Value is A$4.73 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Elixinol Wellness's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-4.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elixinol Wellness (ASX:EXL) has a EV-to-EBITDA of -1.00 as of Jul. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Elixinol Wellness. According to the industry distribution chart, Elixinol Wellness ranks #999999 out of 741 companies in the Drug Manufacturers industry.
Is Elixinol Wellness' EV-to-EBITDA too high?
Elixinol Wellness' current EV-to-EBITDA is -1.00. Based on the distribution chart, Elixinol Wellness ranks #999999 out of 741 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Elixinol Wellness' EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Elixinol Wellness ranks #999999 out of 741 companies for EV-to-EBITDA. This places Elixinol Wellness in the lower half of its industry. The industry median EV-to-EBITDA is 13.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.10, based on 741 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Elixinol Wellness. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elixinol Wellness's current EV-to-EBITDA is -1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elixinol Wellness stock overvalued right now?
Based on GuruFocus' analysis, Elixinol Wellness (ASX:EXL) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.01 — trading 70% below its estimated fair value. The current EV-to-EBITDA is -1.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Elixinol Wellness (ASX:EXL), the current EV-to-EBITDA is -1.00 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Elixinol Wellness Ltd is engaged in the hemp industry, innovating, marketing, and selling hemp-derived nutraceutical, cosmetic, and food products. It operates in the three operating segments of the Americas, Australia, Rest of the World regions of which key revenue is derived from the Australia segment. The Australia segment includes the results from operations of Elixinol Wellness (Byron Bay) Pty Ltd and The Sustainable Nutrition Group Pty Ltd and its subsidiaries. It derives maximum revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EXL has been successfully added to your 
